RGX-019 News - LARVOL Sigma

|||||||||| RGX-019 / Inspirna, RGX-019-MMAE / Inspirna
Targeting myeloid epithelial tyrosine kinase (MERTK) receptor in acute myeloid leukemia using a novel antibody-drug conjugate, RGX-019-MMAE (Section 41) - Mar 5, 2024 - Abstract #AACR2024AACR_7736;
High MERTK expression in monocytic AML suggested that MERTK is a promising therapeutic target in this subtype. RGX-019-MMAE significantly induced AML cell death and produced a synergistic anti-leukemic effect in combination with chemotherapeutic agents and targeted therapy in vitro, suggesting its potential for targeting patients with high-risk AML.

|||||||||| RGX-019 / Inspirna
RGX-019-MMAE, a novel MERTK-targeting antibody-drug conjugate (ADC) with robust anti-tumor efficacy in both solid and liquid tumors. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4801;
RGX-019-MMAE significantly induced AML cell death and produced a synergistic anti-leukemic effect in combination with chemotherapeutic agents and targeted therapy in vitro, suggesting its potential for targeting patients with high-risk AML. Collectively, RGX-019-MMAE

|||||||||| RGX-019 / Rgenix
In vivo efficacy and safety of RGX-019, a MerTK targeting monoclonal antibody (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_588;
Additionally, no clinical hematologic toxicities were observed. Pro-inflammatory macrophage-related cytokines were detected in the plasma after RGX-019 dosing, confirming target engagement in vivo.The MOA and safety profile of RGX-019, along with its high selectivity, affinity, in vivo efficacy, and immunologic activity, support further advancement of RGX-019 as a clinical candidate for development in solid and liquid cancers.



	Diseases Companies Products Productz Mechanisms of Action Sites